Skip navigation.

Keystone Symposium on HIV Vaccines: Why Clinical Trials Are a Sound Investment.

Publication year: 
2010
Author (s): 
Kresge, K
Corporate author: 
IAVI
Publication details: 
Geneva, IAVI, 2010
Publication in: 
IAVI Report; Volume 14, number 2; March-April 2010
Abstract:

Reports on the Keystone Symposium which was held in Banff, Canada, following on the heels of the 17th Conference on Retroviruses and Opportunistic
Infections in February, and the Keystone Symposium on HIV Biology and pathogenesis in January. The HIV Vaccines meeting is widely considered to be the most important of the annual scientific gatherings on the topic, and is a highlight on the crowded conference calendars of many researchers. Discussions this year centered on characterization of the new crop of broadly neutralizing antibodies that were discovered over the past year (see Antibody Fever, page 4). As researchers scrutinize the structures of these antibodies and their binding sites on the virus, they are gaining valuable insights into how these antibodies are able to neutralize so well. At Keystone, researchers reported for the first time that some of these antibodies appear to be highly developed, having acquired several mutations through a process referred to as affinity maturation. This finding could have important implications for the design of vaccine immunogens based on these antibodies.